Generic Name and Formulations:
Ethosuximide 250mg; caps.
Indications for ZARONTIN:
Initially: 500mg daily. Increase every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses.
<3yrs: not established. 3–6yrs: initially 250mg daily. >6yrs: initially 500mg daily. Increase both every 4–7 days by 250mg daily according to response; max 1.5g daily in divided doses. Usual maintenance: 20mg/kg/day in divided doses.
Impaired hepatic or renal function. May precipitate tonic-clonic seizures. Discontinue at 1st sign of rash; consider alternative therapy if signs/symptoms of Stevens-Johnson syndrome occurs. Evaluate immediately if signs/symptoms of DRESS/multi-organ hypersensitivity develop; discontinue if no alternative etiology. Monitor for depression, suicidal ideation, unusual changes in mood/behavior. Monitor CBCs, kidney and liver function periodically. Change dose gradually. Pregnancy. Nursing mothers: not recommended.
Monitor phenytoin, phenobarbital, valproic acid, other AEDs.
Blood dyscrasias, drowsiness, ataxia, dizziness, headache, GI upset, CNS and psychiatric effects, rash (may be fatal), SLE, DRESS, gingival hyperplasia.
Caps, syrup (YES)
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL